pyrazines has been researched along with Glucose Intolerance in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 9 (90.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Diamant, M; Heymans, MW; Mari, A; Muskiet, MH; Ouwens, DM; Pouwels, PJ; van Genugten, RE; van Raalte, DH | 1 |
| Ares-Carrasco, S; Caro-Vadillo, A; Egido, J; Iborra, C; Lorenzo, O; Picatoste, B; Ramírez, E; Tuñón, J | 1 |
| Best, C; Laciny, E; Reeds, DN; Royal, M; Struthers, H; Yarasheski, KE | 1 |
| Basu, R; Bock, G; Cobelli, C; Dalla Man, C; Deacon, CF; Giesler, PD; Holst, JJ; Laugen, J; Micheletto, F; Rizza, RA; Toffolo, G; Vella, A | 1 |
| Aleksunes, LM; Goedken, MJ; Klaassen, CD; Reisman, SA; Yeager, RL | 1 |
| Abel, T; Fehér, J | 1 |
| Coben, J; Dobrian, AD; Galkina, EV; Leone, KA; Lindsay, JW; Ma, K; Ma, Q; Nadler, JL | 1 |
| Fan, K; Hou, J; Jin, W; Ma, J; Tan, Y; Wu, J; Xiao, W; Yu, B; Zheng, D | 1 |
| Brismar, K; Efendic, S; Hage, C; Lundman, P; Mellbin, L; Rydén, L | 1 |
| Ahrén, B | 1 |
1 review(s) available for pyrazines and Glucose Intolerance
| Article | Year |
|---|---|
[A new therapeutic possibility for type 2 diabetes: DPP-4 inhibitors (sitagliptin)].
Topics: Administration, Oral; Blood Glucose; Cell Proliferation; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucose Intolerance; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Pyrazines; Sitagliptin Phosphate; Triazoles | 2010 |
4 trial(s) available for pyrazines and Glucose Intolerance
| Article | Year |
|---|---|
Does dipeptidyl peptidase-4 inhibition prevent the diabetogenic effects of glucocorticoids in men with the metabolic syndrome? A randomized controlled trial.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Fasting; Glucocorticoids; Glucose Intolerance; Humans; Insulin Resistance; Islets of Langerhans; Male; Metabolic Syndrome; Middle Aged; Postprandial Period; Prednisolone; Pyrazines; Sitagliptin Phosphate; Triazoles | 2014 |
Sitagliptin Reduces Inflammation and Chronic Immune Cell Activation in HIV+ Adults With Impaired Glucose Tolerance.
Topics: Adipokines; Adult; Chemokines; Endothelial Progenitor Cells; Female; Glucose Intolerance; HIV Infections; HIV-1; Humans; Hypoglycemic Agents; Inflammation; Lymphocyte Activation; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles | 2015 |
The effect of DPP-4 inhibition with sitagliptin on incretin secretion and on fasting and postprandial glucose turnover in subjects with impaired fasting glucose.
Topics: Blood Glucose; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Fasting; Female; Glucose Intolerance; Humans; Incretins; Male; Middle Aged; Placebos; Postprandial Period; Pyrazines; Sitagliptin Phosphate; Triazoles | 2010 |
Sitagliptin improves beta-cell function in patients with acute coronary syndromes and newly diagnosed glucose abnormalities--the BEGAMI study.
Topics: Acute Coronary Syndrome; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Follow-Up Studies; Glucagon-Like Peptide 1; Glucose Intolerance; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Prospective Studies; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2013 |
5 other study(ies) available for pyrazines and Glucose Intolerance
| Article | Year |
|---|---|
Sitagliptin reduces cardiac apoptosis, hypertrophy and fibrosis primarily by insulin-dependent mechanisms in experimental type-II diabetes. Potential roles of GLP-1 isoforms.
Topics: Animals; Apoptosis; Cardiomegaly; Cardiotonic Agents; Cells, Cultured; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Disease Models, Animal; Drug Evaluation, Preclinical; Fibroblasts; Fibronectins; Fibrosis; Glucagon-Like Peptide 1; Glucose Intolerance; Hypoglycemic Agents; Insulin; Male; Metformin; Myocardium; Myocytes, Cardiac; PPAR delta; Protein Isoforms; Pyrazines; Rats; Sitagliptin Phosphate; Triazoles | 2013 |
Nuclear factor erythroid 2-related factor 2 deletion impairs glucose tolerance and exacerbates hyperglycemia in type 1 diabetic mice.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Glucose Intolerance; Glucose-6-Phosphatase; Hyperglycemia; Insulin; Liver; Liver Glycogen; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; NAD(P)H Dehydrogenase (Quinone); NF-E2-Related Factor 2; Pancreas; Phosphoenolpyruvate Carboxykinase (GTP); Pyrazines; Pyruvate Kinase; RNA, Messenger; Thiones; Thiophenes; Urodynamics | 2010 |
Dipeptidyl peptidase IV inhibitor sitagliptin reduces local inflammation in adipose tissue and in pancreatic islets of obese mice.
Topics: Adipocytes; Adipose Tissue; Adiposity; Animals; Anti-Inflammatory Agents; Body Weight; Cytokines; Dipeptidyl-Peptidase IV Inhibitors; Flow Cytometry; Glucose; Glucose Intolerance; Glucose Tolerance Test; Immunohistochemistry; Inflammation; Insulin; Islets of Langerhans; Macrophages; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Neutrophil Infiltration; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; Sitagliptin Phosphate; Triazoles | 2011 |
Combination of mangiferin and dipeptidyl peptidase-4 inhibitor sitagliptin improves impaired glucose tolerance in streptozotocin-diabetic rats.
Topics: Animals; Diabetes Mellitus, Experimental; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucagon-Like Peptide 1; Glucose Intolerance; Insulin; Islets of Langerhans; Male; Pyrazines; Rats; Rats, Sprague-Dawley; Sitagliptin Phosphate; Streptozocin; Triazoles; Xanthones | 2012 |
Reducing plasma free fatty acids by acipimox improves glucose tolerance in high-fat fed mice.
Topics: Animals; Blood Glucose; Body Weight; Dietary Fats; Fatty Acids, Nonesterified; Female; Glucose Intolerance; Glucose Tolerance Test; Hypolipidemic Agents; Injections, Intraperitoneal; Insulin; Mice; Mice, Inbred C57BL; Pyrazines | 2001 |